Colliers Securities Thinks Motus Gi Holdings’ Stock is Going to Recover


Colliers Securities analyst Kyle Bauser reiterated a Buy rating on Motus Gi Holdings (MOTS) today and set a price target of $2.50. The company’s shares closed last Thursday at $0.92, close to its 52-week low of $0.68.

According to TipRanks.com, Bauser is a 2-star analyst with an average return of 0.6% and a 45.1% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Chembio Diagnostics.

Motus Gi Holdings has an analyst consensus of Strong Buy, with a price target consensus of $2.26, implying a 128.3% upside from current levels. In a report issued on April 30, Piper Sandler also maintained a Buy rating on the stock with a $2.50 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.74 and a one-year low of $0.68. Currently, Motus Gi Holdings has an average volume of 5.3M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts